Lymphatic vessel density and VEGF-C expression are significantly different among benign and malignant thyroid lesions by Garcia, Eduardo Anselmo et al.
Lymphatic Vessel Density and VEGF-C Expression
are Significantly Different Among Benign and Malignant
Thyroid Lesions
Eduardo Anselmo Garcia & Kleber Simões & Alda Wakamatsu &
Rodrigo Albergaria Ressio & Venâncio Avancini Ferreira Alves &
Adhemar Longatto-Filho & Roberto Souza Camargo
# Springer Science+Business Media, LLC 2010
Abstract Thyroid cancer is the most frequent endocrine
neoplasia worldwide. The route for metastasis and loco-
regional invasion preferentially occurs by lymphatic ves-
sels. For this reason, the assessment of lymphatic vessel
density (LVD) is supposed to represent both a prognostic
parameter and also a potential therapeutic target. In order to
evaluate the value of LVD in benign and malignant thyroid
lesions, we analyzed 110 thyroidectomy specimens using D2-
40, a specific marker for lymphatic vessels and vascular
endothelial growth factor C (VEGF-C), the most potent
molecule of lymphatic proliferation. LVD was significantly
different between papillary and follicular carcinomas in total
(p=0.045) and peritumoral area (p=0.042). Follicular ade-
noma and follicular carcinoma showed an important differ-
ence of intra- (p=0.019) and peritumoral (p=0.033) LVD.
VEGF-C was more markedly expressed in malignancies than
in benignant lesions (p=0.0001). Almost all cancers with
high positive VEGF-C expression also exhibited increased
peritumoral LVD (p=0.049) when compared with the
benignant lesions. Indeed, the high peritumoral LVD of
malignant thyroid lesions is an important finding for surgery
planning and supports the practice of total thyroidectomy in
malignant thyroid neoplasm’s since the lymphatic peritu-
moral vessels definitely are an escape path for tumor cells.
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Introduction
Several mechanisms can mediate tumor cell dissemination,
including hematogenous or lymphatic spread, local invasion,
and direct seeding of body cavities or surfaces [1]. Increased
lymphatic vessel density (LVD) is commonly associated with
more aggressive behavior of malignant neoplasias which
commonly escape from the primary site preferentially through
lymphatic vessels due to its structural features without
cohesive pericytes and thin endothelial wall [2]. Evaluation
of lymphangiogenesis in cancer is relatively recent when
compared to angiogenesis, mainly due to the lack of specific
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markers to identify lymphatic endothelial cells. D2-40
monoclonal antibody [3, 4] proved to be a selective marker
for lymphatic endothelium, allowing identification of lym-
phatic vessels in formalin-fixed paraffin-embedded tissue,
and consequently facilitating the studies of LVD in solid
tumors [4, 5]. This is important because identification of
lymphatic vessels on morphological basis alone is not
consistent due to overlap with blood vessels capillaries [6–8].
Furthermore, adequate distinction between these two types of
vessels is crucial for understanding the biology of interaction
between tumors and neoformed vascular structures, poten-
tially contributing to the specific tailoring of therapeutical
strategies in the future. This approach highlights the
important differences between blood and lymphatic vessels
regarding their receptors, with potential effects on diagnostic
evaluation as well as prognostication [2].
In recent years, a number of evidences provided better
understanding of the role and themolecular mechanisms related
to development and maintenance of lymphatic vessels and also
their role in different pathologic conditions [1, 9]. The vascular
endothelial growth factor C (VEGF-C) is involved in
proliferation and migration of endothelial cells, increased
vascular permeability and lymphangiogenesis [10, 11].
VEGF-C and its receptor VEGFR-3 were shown to be
essential to lymphatic vessels development in embryos [12]
and in the maintenance of lymphatic endothelial cells in adults
[13]. Some reports showed VEGF-C expression in several
types of human tumors and a correlation between VEGF-C
expression in primary tumors and nodal metastasis [8, 14, 15].
Thyroid carcinomas are the most frequent endocrine
malignancy, mainly affecting women, with an estimated
37,200 new cases and 1,630 deaths due to the thyroid cancer
in United State of America in 2009 [16]. Most thyroid tumors
follow an indolent clinical course with favorable prognosis
[17–20]. Although it has been already well characterized that
metastatic dissemination differs between papillary and
follicular carcinoma [18, 21], studies on differential distri-
bution of these two types of vascular structures in common
benign and malignant thyroid lesions are relatively scant in
literature. LVD and expression of VEGF-C in malignant and
benign thyroid lesions are poorly studied and are still far to
be fully understood [21]. In addition, intra- and peritumoral
LVD show different patterns and prognostic significance
related to the tumor behavior in different types of tumors
[22]. However, few data are available regarding LVD and
VEGF-C expression in thyroid lesions, and for the majority
of them, the results are conflicting [21, 23].
The objective of the present study was to determine the
LVD pattern assessed by D2-40 antibody in malignant and
benignant thyroid lesions, exploring potential differences
between LVD distributions among the different types of
thyroid lesions and correlated them with VEGF-C expres-
sion and clinicopathological features.
Materials and Methods
The casuistic comprised a series of formalin-fixed, paraffin-
embedded tissues from 110 patients submitted to thyroid-
ectomy. The frequency of different thyroid lesions was: 34
(30.9%) goiters, 17 (15.5%) thyroiditis, six (5.5%) follic-
ular adenomas, 49 (44.5%) papillary carcinomas, and four
(3.6%) follicular carcinomas (none of them were classified
as minimally invasive). The papillary carcinoma samples
comprised 33 samples of papillary carcinoma of conven-
tional form, 11 samples of follicular variant of papillary
carcinoma, one sample of tall cell variant of papillary
carcinoma and four samples of papillary microcarcinoma.
For statistical purposes, all papillary carcinomas were
grouped as a single type. All patients were submitted to
surgical resection by the same surgeon (RSC) and the
diagnoses were categorized according World Health
Organization classification [24] by one of the authors
(KSES).
Pathological features herein evaluated included macro-
scopic presentation, principal site of the tumor, histological
type, status of resection margins, and lymph node status.
Immunohistochemistry
Thyroid tissue samples were analyzed for D2-40 immuno-
histochemical expression using monoclonal D2-40 clone
(DAKO Corporation, Carpinteria, CA, USA) specific
antibody. Comparisons of D2-40 expression in intra- and
peritumoral neoplastic areas were quantified. Also, D2-40-
LVD from benign lesions as adenoma, goiter, and thyroid-
itis were evaluated.
The lymphatic molecular player VEGF-C was analyzed
in all non-malignant and malignant cases with rabbit
polyclonal anti-VEGF-C antibody (Zymed Laboratories,
San Francisco, CA, USA). Slides from all 110 specimens
were reviewed and mapped, and tissue microarrays were
building using manual tissue arrayer (MTA-1 Beecher
Instrument, Silver Spring, MD, USA). Representative areas
of the thyroid lesions were selected and cores of 1.0 mm
in diameter were twice sampled and arranged at 0.3 mm,
one from each other, in the recipient paraffin block. A
database was build for every block produced, including
the coordinates of each core and case of origin. The
positive expressions of VEGF-C were semi-quantitatively
assessed.
D2-40 and VEGF-C Immunohistochemistry
D2-40 and VEGF-C protocol followed Longatto-Filho et
al. [25] recommendations with slight modifications. Brief-
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ly, deparaffinized and rehydrated sections were immersed
in 0.01 M citrate buffer (pH 6.0) and heated at 98°C for
20 min for epitope–antigen retrieval. Subsequently,
endogenous peroxidase was blocked with 0.3% hydro-
gen peroxide in methanol. Primary antibody incubation
step was done with 1:200 dilution for D2-40 and
VEGF-C, overnight at 4°C. The amplification method
used was Novolink system (Novocastra Laboratories
Ltd, Newcastle Upon Tyne, UK). Visualization was
developed with 3,3’-diamino-benzidine (DAKO Corpo-
ration, Carpinteria, CA, USA) and counterstaining with
Harris’ hematoxylin (Merck, Dermstadt, Germany).
Negative controls were obtained by omitting the primary
antibody incubation step; and tonsil was used as positive
controls.
Immunohistochemical Evaluation
Immunohistochemical reaction for D2-40 was considered
positive when the staining decorated the cytoplasm of
lymphatic endothelial cells. The evaluation was performed
blindly and LVD was assessed as postulated by Weidner et
al. [26] with slight modifications. LVD was defined as a
single endothelial cell or a cluster of endothelial cells
positive for D2-40, sitting around a visible lumen clearly
separate from adjacent microvessels and from other
connective tissue components. Additionally, as lymphatic
vessels could generally appear as distorted and over-
lapped structures in cancer setting, the packed vessels
were assumed as one lymphatic unit. Number of vessels
was determined at 200× magnification, with the mean
and median for ten fields calculated and defined as
LVD.
Expression of VEGF-C by neoplastic and non-neoplastic
samples was semi-quantified under 200× magnification,
considering membrane and/or cytoplasmic staining of
normal, follicular, or malignant thyroid cells. The evalua-
tion was performed blindly and the tissue microarray spot
of each sample were fully analyzed. The following
grading system was used: negative (0) absence of
expression, + positive staining with expression in up to
10% of cells, ++ positive expression in over 10% up to
25% of cells, +++ positive expression in over 25% up to 50%
of cells, and ++++ positive expression in over 50% of cells.
For statistical analyses purposes, VEGF-C expression was
dichotomized in two categories: negative (0 to up 10% of
positivity) and positive (over 10% of positive reaction).
Statistic Analysis
The data were obtained from the available information on
patient’s files and tissue samples revised. Accordingly, the
statistics were based on these variables.
The relationship between D2-40 expression, VEGF-C,
and clinicopathologic features were examined using Pear-
son’s chi-square (χ2) test or Fisher’s exact test when
appropriate and considered significant when p<0.05. The
Mann–Whitney test was used for continuous variables.
Frequencies Percent
Gender (n=110) M 23 21%
F 87 79%
Age (years, n=104) <45 55 52.9%
≥45 49 47.1%
Mean age (± SD, n=104) 45.9+14.9
Diagnosis (n=110) Goiter 34 30.9%
Thyroiditis 17 15.5%
Follicular adenoma 6 5.5%
Papillary thyroid carcinoma 49 44.5%
Follicular carcinoma 4 3.6%
Capsular invasion (n=35) Present 16 45.7%
Non-detected 19 54.3%
Vascular invasion (n=44) Present 12 27.30%
Non-detected 32 72.70%
Peri-thyroidal soft tissue compromise (n=34) Present 6 17.6%
Non-detected 28 82.4%
Lymph node status (n=35) Negative 21 60%
Positive 14 40%
Table 1 Summary of clinico-
pathologic features
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Data were analyzed with Statistical Package of Social
Sciences software, version 13.0.
Results
A total of 110 thyroidectomy specimens were evaluated.
Women were 3.7-fold more likely to be affected than men
(87 female and 23 male patients) and the mean age was
45.9 years old. Capsular invasion were present in 16
(45.7%) and not detected in 19 (54.3%) samples; vascular
invasion were present in 12 (27.3%) and not detected in 32
(72.7%) samples; peri-thyroidal soft tissue compromise
were present in six (17.6%) and non-detected in 28 (82.4%)
samples; and lymph node status were positive in 14 (40%)
and negative 21 (60%) samples (Table 1). The tumors were
predominantly found in the right or in the left lobe, each
one of them with similar frequencies: 32.7% and 30.8%,
Fig. 1 The D2-40 antibody stains specifically intratumoral lymphatic
endothelial cells in papillary carcinoma (a) 40× and follicular
carcinoma (d) 40×. The D2-40 antibody stains specifically peritumoral
lymphatic endothelial cells in follicular carcinoma (g) 20×. The
VEGF-C antibody strongly (++++) and specifically stains tumoral
cells in papillary carcinoma (b) 40× and follicular carcinoma (e) 40×.
VEGF-C antibody specifically weak (+) stain in goiter (h) 20×.
Hematoxylin and eosin (HE) staining of papillary carcinoma (c) 40X,
follicular carcinoma (f) 40× and goiter (i) 20×. These HE images are
from the same samples represented in b, e, and h, respectively
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respectively. The other cases affected right lobe, isthmus,
and left lobe in different combinations, but none of these
combinations were greater than 10%.
The immunohistochemical expression of D2-40 and
VEGF-C in thyroid lesions was analyzed in all samples as
exemplified in Fig. 1.
Different lesions showed different LVD patterns as
summarized in Table 2. Among neoplasm’s, peritumoral
LVDs mean were always higher when compared with the
intratumoral LVD in the same group. When analyzed in
peers, LVD showed significant differences between papil-
lary and follicular carcinomas in total (p=0.045) and
peritumoral LVD (p=0.042). Follicular adenoma and
follicular carcinoma showed an important difference of
intra (p=0.019) and peritumoral (p=0.033) LVD (Table 3).
Total, intratumoral or peritumoral LVDs did not differ
according to the gender, age, vascular invasion, or lymph
node status of patients, although the capsular invasion
correlate with peritumoral LVD (p=0.045).
The VEGF-C show different patterns of immunoreactivity
in all samples and was markedly expressed in both papillary
(80.9% positive) and follicular carcinoma (100% positive)
when compared to goiter (41.2% positive), thyroiditis (62.5%
positive), and follicular adenoma (16.7% positive, p=0.0001;
Table 4). The more aggressive tumor subtypes, like the tall cell
variant of papillary carcinoma, and almost all samples with high
positive VEGF-C expression exhibit increased LVD when
compared with the negative cases. However, statistical signif-
icance was found only when comparing VEGF-C expression
with peritumoral LVD (p=0.049, Table 5). VEGF-C immuno-
reactivity did not differ according to the gender, age, vascular
invasion, capsular invasion, or lymph node status.
Discussion
Thyroid cancer usually follows an indolent clinical course
and is associated with good prognosis, with few examples
emerging as aggressive tumors as anaplastic or medullary
carcinomas [17–19]. Papillary carcinomas generally shows
good prognosis whereas follicular and some papillary
subtypes have more aggressive behavior [27]. Increased
lymphatic vessel density is assumed as one of the most
important parameters associated to the aggressive behavior
of malignant tumors [22]. Nevertheless, we failed to
corroborate this rationale because papillary carcinoma and
benign lesions showed similar LVD, comparatively. How-
ever, the overall findings clearly demonstrated that thyroid
lesions have different LVDs, which opens a new exciting
view to explore the differences between them based on
specific lymphatic vessels development. Remarkably, we
identified a significant difference in LVD between follicular
adenoma and follicular carcinoma. This is important
because it is well-known that this discrimination is difficult
to be assessed by morphological criteria, the carcinoma
diagnosis is only confirmed if truly capsular invasion is
observed [28, 29]. Our results are confirmed, in part, by
those reported by Giorgadze and colleagues that showed
that LVD determination can be a valuable tool to
discriminate follicular lesions of thyroid gland [21]. Of
note, we have to stress that peritumoral and intratumoral
LVD were significantly different between these neoplasms
(p=0.033 and 0.019, respectively), but not the total LVD (p=
0.054), probably due to the very limited number of cases.
Additionally, we also investigated the expression of
VEGF-C, one of the major players in lymphatic vessel
LVD total LVD intra LVD peri
Mean ± SD P value Mean ± SD P value Mean ± SD P value
Papillary thyroid carcinoma 8.4±2.7 7.0±3.0 9.0±3.8
0.045* 0.083 0.042*
Follicular carcinoma 12.2±4.1 11.3±5.9 12.3±1.9
Follicular adenoma 6.8±2.8 5.3±2.1 8.0±3.5
0.054 0.019* 0.033*
Follicular carcinoma 12.2±4.1 11.3±5.9 12.3±1.9
Table 3 Total, intra- and peri-
tumoral LVD comparison by
diagnosis
Total Intratumoral Peritumoral
mean ± SD mean ± SD mean ± SD
Goiter 11.2±4.2 – –
Thyroiditis 10.3±5.2 – –
Follicular adenoma 6.8±2.8 5.3±2.1 8.0±3.5
Papillary thyroid carcinoma 8.4±2.7 7.0±3.0 9.0±3.8
Follicular carcinoma 12.2±4.1 11.3±5.9 12.3±1.9




sprout, to verify some particular differences among the
thyroid lesions we studied. Of interest, we also hypothe-
sized that the well recognized more aggressive behavior of
thyroid tumors in males could be attributed to the enhanced
LVD stimulated by augmented VEGF-C expression in these
patients; however, this was not supported by our results
since LVD and VEGF-C expression for both genders had
similar values.
Peritumoral LVDs did not correlate with vascular
invasion or other clinicopathological features indicative of
aggressiveness such as lymph node metastases, which is
believed to be associated to the good prognoses in general
imputed for thyroid cancer [23]. However, we observed that
capsular invasion was related to higher peritumoral LVD
(p=0.045). This result endorses previous reports with solid
tumors where peritumoral, but not intratumoral LVD is
associated with more aggressive cancer behavior [4, 7].
Additionally, intratumoral lymphangiogenesis is presumed
to form large, weak, and distorted new vessels, implicating
a new formed fragile vascular network. Thus, it is
reasonable to assume that peritumoral LVD is more tailored
to provide competent routes for malignant cells escape.
Functional lymphatics at the tumor margin is believed to be
sufficient for promoting metastasis by offering a large area
for tumor cell escape [4].This fact was clearly evidenced by
Padera and colleagues which studied the influence of
tumoral pressure in intratumoral lymphatic vessels, show-
ing that these vessels were collapsed and unable to support
the malignant cells spread [30].
Our results showed that peritumoral LVD was signifi-
cantly higher in follicular carcinoma than in papillary
carcinoma (p=0.042), but no other conjecture could be
extract of this limited observation.
The significance of VEGF-C expression in the thyroid
neoplasms is contentious [23]. Despite that, we found some
interesting correlations which indicate VEGF-C as an
important feature contributing to thyroid neoplasm devel-
opment. Notably, VEGF-C was markedly expressed in both
papillary and follicular carcinoma, which significantly
separated malignant from benign lesions. Parallel to this
statement, it was also important to highlight that follicular
carcinoma importantly expressed more VEGF-C than its
benign counterpart, follicular adenoma. The majority of
malignant cases with increased LVD also exhibited high
VEGF-C expression, with statistical significance in peritu-
moral LVD (p=0.049). A higher VEGF-C immunoreactiv-
ity at the tumor borders have been demonstrated in several
types of cancers [4, 31, 32]. This finding suggests that
VEGF-C expressed by thyroid tumor cells at the invasive
front can directly drive peritumoral lymphangiogenesis [7].
This assumption, however, was not ratified in the present
work. Additional data with whole tumor samples of more
robust casuistic of thyroid lesions would clarify this
interesting point. The contradicting data about LVD and
thyroid carcinomas maybe due to differences samples
selection and LVD quantification methodology. Also, these
contentious results might be related to the inherent complex
mechanisms of lymphangiogenesis and metastatic spread.
Further studies evaluating the molecular biology involved
with lymphatic vascularization network in thyroid tumors
progression should be conducted in order to clarify the
differences herein observed.
Table 5 Comparison between VEGF-C expression and LVD
VEGF-C LVD total LVD intra LVD peri
Mean ± SD P value Mean ± SD P value Mean ± SD P value
Negative (<10%) 90.9±439.2 (n=40) 0.246 61.6±289.0 (n=14) 0.303 75.4+414.6 (n=14) 0.049*
Positive (>10%) 99.5±361.5 (n=67) 73.9±356.0 (n=43) 97.2±297.5 (n=43)
VEGF-C
Negative (<10%) Positive (>10%) P value
Goiter (n=34) 58.8% 41.2%
Thyroiditis (n=16) 37.5% 62.5%
Follicular adenoma 83.3% 16.7%
(n=6) 0.0001*
Papillary thyroid carcinoma (n=47) 19.1% 80.9%
Follicular carcinoma (n=4) 0.0% 100.0%
Table 4 VEGF-C expression in
different thyroid lesions
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